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Abstract
Background: In the developmental stage of laparoscopic cholecystectomy (LC) it was considered 'unsafe'
or 'technically difficult' to perform laparoscopic cholecystectomy for acute cholecystitis (AC). With
increasing experience in laparoscopic surgery, a number of centers have reported on the use of
laparoscopic cholecystectomy for acute cholecystitis, suggesting that it is technically feasible but at the
expense of a high conversion rate, which can be up to 35 per cent and common bile duct lesions.
The HARMONIC SCALPEL(R) (H) is the leading ultrasonic cutting and coagulating surgical device, offering
surgeons important benefits including: minimal lateral thermal tissue damage, minimal charring and
desiccation.
Harmonic Scalpel technology reduces the need for ligatures with simultaneous cutting and coagulation:
moreover there is not electricity to or through the patient Harmonic Scalpel has a greater precision near
vital structures and it produces minimal smoke with improved visibility in the surgical field.
In retrospective series LC performed with H was demonstrated feasible and effective with minimal
operating time and blood loss: it was reported also a low conversion rate (3.9%).
However there are not prospective randomized controlled trials showing the advantages of H compared
to MD (the commonly used electrical scalpel) in LC.
Methods/Design: Aim of this RCT is to demonstrate that H can decrease the conversion rate compared
to MD in LC for AC, without a significant increase of morbidity.
The patients will be allocated in two groups: in the first group the patient will be submitted to early LC
within 72 hours after the diagnosis with H while in the second group will be submitted to early LC within
72 hours with MD.
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Background
In the developmental stage of laparoscopic cholecystec-
tomy it was considered 'unsafe' or 'technically difficult' to
perform laparoscopic cholecystectomy for acute cholecys-
titis [1,2].
With increasing experience in laparoscopic surgery, a
number of centers have reported on the use of laparo-
scopic cholecystectomy for acute cholecystitis, suggesting
that it is technically feasible but at the expense of a high
conversion rate, which can be up to 35 per cent [3,4] and
common bile duct lesions [5].
The HARMONIC SCALPEL® (H) is the leading ultrasonic
cutting and coagulating surgical device, offering surgeons
important benefits including: minimal lateral thermal tis-
sue damage, minimal charring and desiccation.
H technology reduces the need for ligatures with simulta-
neous cutting and coagulation: moreover there is not elec-
tricity to or through the patient
H has a greater precision near vital structures and it pro-
duces minimal smoke with improved visibility in the sur-
gical field. [6]
In retrospective series LC performed with H was demon-
strated feasible and effective with minimal operating time
and blood loss: it was reported also a low conversion rate
(3.9%). [6]
However there are not prospective randomized controlled
trials showing the advantages of H compared to Monopo-
lar Diathermy (MD – the most commonly used electrical
scalpel) in LC.
Aim of this RCT is to demonstrate that H can decrease
conversion rate compared to MD in LC for AC, without a
significant increase of morbidity.
Methods
The study project is a prospective, randomized investiga-
tion. The study will be performed in the Department of
Emergency Surgery St Orsola-Malpighi University Hospi-
tal (Bologna, Italy), a large teaching institutions, with the
participation of all surgeons who accept to be involved in.
The Ethic Committee of St. Orsola Malpighi University
Hospital has approved the study protocol on June 24th
2008. The study and its Informed Consent form have
been judged by the Committee to be ethically and scien-
tifically satisfactory as well as correct and adequate to the
aims.
The patients will be allocated in two groups: in the first
group the patient will be submitted to early LC within 72
hours after the diagnosis with H while in the second
group will be submitted to early LC within 72 hours with
MD.
The randomization will be obtained through computer-
generated schedule. Blocked randomization is used to
ensure close balance of the numbers in each group at any
time during the study. The result of this randomization
will be sealed in numbered envelopes, inserting inside a
cardboard to ensure that they are opaque. After cholecys-
titis diagnosis if the patient fulfils the inclusion criteria the
responsible surgeon will ask the patient to partecipate to
the study. If the patient agree, he/she will sign the
informed consent. After patient's consent the randomiza-
tion will be carried out. The responsible surgeon will
record the patient name (and number). [7-9]
All eligible patients will be recorded. [10]
Statistical Methods and Power Calculations
By using StatCal of Epi INFO 2000 software package
(Centers for Disease Control and Prevention, Atlanta, GA,
USA), a sample size of 21 patients for each group (42
patients for the whole study) has been calculated to reach
a confidence level of 95% with a power of 80%, suppos-
ing that the hospital stay for LC with H the conversion rate
can be reduced from 35% to 3%.
Analysis of data is by intention-to-treat. It will be specified
when and how any deviations from randomised alloca-
tion, false inclusions, or missing outcomes have been
handled. Repeated measures of the outcome will be per-
formed with complete case analyses, potentially excluding
individuals with some follow-up data, Eventual missing
outcomes will be imputed using baseline values or by
assuming that all missing participants have the same risk
as the observed participants in the control group.
Data are expressed as numbers (%) and means (SD). The
results of the two groups in comparison are analyzed using
the Pearson's chi-square test and Fisher exact test, as appro-
priate, for proportions in case of discrete data. Fisher exact
test is used when the data are very unequally distributed
among the cells of the table or the expected frequency of
any cell is less than 5 or the total N is less than 50. For
means in case of continuous numerical data, the independ-
ent samples T test and the Mann-Whitney U-test are used,
respectively for data normally and non-normally distrib-
uted. The data are previously tested for normality by the
Kolmogorov-Smirnov test. For multivariate analysis the
stepwise logistic regression is applied. A p-value of < 0.005
is in any case considered to be statistically significant.
Forward selection has been used as variable selection
method; it will include all the baseline variables and all
baseline variables are assessed for imbalance. The finalTrials 2009, 10:34 http://www.trialsjournal.com/content/10/1/34
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model only contain variables with a p-value less than
0.05. Imbalances of baseline variables are defined com-
paring the groups using t tests for continuous variables
and χ2 tests for categorical variables. The adjustments are
based upon the stratified logrank test or analysis of covar-
iance. [11-13]The primary outcome is the conversion rate.
Secondary outcomes are: intra-operative and post-opera-
tive morbidity and mortality, operative time and intra-
operative blood losses.
All the secondary outcomes, including morbidity and mor-
tality, operative time and blood losses, will be controlled as
well for imbalances, (i.e. age, previous comorbidities, antico-
agulant therapies, previous abdominal surgery).
Inclusion criteria are:
￿ Adult patients (>18 years)
￿ Clinical (pain, fever > 37.5°C, WBC > 10.000/
microL), and ultrasound evidence of cholecystitis
￿ ASA I-III patients
￿ Informed consent
￿ Less than 72 h from the onset
Exclusion criteria are:
￿ Informed consent refusal
￿ Choledocholithiasis
￿ Generalized peritonitis
￿ Previous abdominal surgical procedures
￿ Patients with an intra-operative findings of different
pathology will be excluded from the study
￿ Apache II score > 10
Intervention
Preoperative data collected will include patient demo-
graphics and comorbidity conditions (genitourinary, car-
diac, pulmonary, gastrointestinal, renal, or
rheumatologic) and a detailed history of symptom onset.
The procedure was performed by a surgeon that had per-
formed at least 50 LCs.
On admission, the patients were started on cefotaxime, 2
g IV every 12 h, which was continued postoperatively
according to NNISS score.
The standard four-trocar operative technique is used for
LC for acute cholecystitis.
When the gallbladder is distended it will be first aspirated.
To allow a good hold on the gallbladder larger graspers
will be inserted through a 5 mm right lower port. The
cystic artery and duct are clip-ligated in the MD group
whereas in the H group cystic artery and duct are closed by
H. In the H group the surgeon will use only H, whereas in
the MD group the surgeon will use only MD. The gallblad-
der and intraperitoneal "dropped" stones are collected in
an endoscopic bag and extracted through the umbilical
cannula site, which can be extended. A closed system suc-
tion drain is left. Fascial closure is attempted only at the
umbilical cannula site. The skin at all the cannula sites are
closed with staples. Conversion to laparotomy will be
decided by the operating surgeon and each conversion
will be motivated.
Data Collection
Patients' data sheets are generated containing demo-
graphic data and preoperative, operative, and postopera-
tive information.
Pre-operative notes concern the history of gallbladder
stones, the presence of associated diseases (cardiac, hyper-
tension, diabetes, malignancy), duration of gallbladder
complaints (as an indication for the onset of the disease),
finding of a palpable gallbladder, temperature, and labo-
ratory results of WBC count, serum bilirubin, gamma GT,
CRP, IL-6 and alkaline phosphatase.
Ultrasound findings are also reported.
Operative data of concern are macroscopic findings (of
acute cholecystitis, gangrenous cholecystitis, hydrops, and
empyema of the gallbladder), the presence of small stones
(< 1 cm diameter) or large bile stones (> 1 cm diameter),
information regarding perforation of the gallbladder and
intraperitoneally "lost" stones, reasons for conversion,
and duration of surgery. Postoperative notes of interest
included the use of nasogastric tubes and drains, the
amount of analgesics used, (evaluation of pain with VAS
score), complications, and length of hospital stay.
Complications are classified as surgical infections (wound
infection, subphrenic or subhepatic abscess); noninfec-
tious surgical problems (e.g., bile duct injury, hemor-
rhage); remote infections (urinary or respiratory); and
miscellaneous problems (e.g., atelectasis, deep vein
thrombosis, AMI, CVA, etc). The collected information are
entered into a database as either continuous or categorical
variables for statistical analysis. Following the operative
procedure, a normal sterile dressing will be applied to
cover the abdomen.Trials 2009, 10:34 http://www.trialsjournal.com/content/10/1/34
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A second surgical team, aware of the operative findings
but not the surgical dissection instrument, then will
assume the care of the patient. Postoperative care and
ability to be discharged from the hospital will be deter-
mined by the second surgical team. The primary operative
team will be in every moment available for emergent con-
sultation.
Patient discharge will be base on good medical practice
criteria: 1) apyrexia 2) absence of diseases requiring hos-
pitalisation 3) return of bowel function 4) patient's com-
pliance.
No Placebo drugs are used for this study.
Every patient will be asked to sign the Informed Consent.
In the informed consent form, patients will receive all the
information about the study protocol, the confidential
nature of personal data and will fill up a questionnaire
before signing or refuse.
There will be not inconveniences caused to the patients.
No incentives are planned for the patients regarding the
operation or the follow-up.
All the medical informations obtained from the patients
will be kept confidentially among the research scientists
conducting the study.
The patients will be free to withdraw from the study,
whenever they want without any obligation.
The study will be stopped in case of newly discovered sta-
tistically significant advantages in one group.
The aim of the study is to demonstrate that H can reduce
conversion rate compared to MD in LC for AC but also dif-
ferences in terms of morbidity, mortality, operation time,
hospital stay, postoperative pain, return to normal activity
will be evaluated.
The primary endpoints of our study will be:
A) To evaluate the conversion rate
B) To evaluate morbidity, mortality, operation time
C)  To evaluate hospital stay, postoperative pain,
return to normal activity
The onset of any other complications will be recorded
intraoperatively, postoperatively, at discharge, at 7-days,
1-month and 6-months.
The side effects that could have observed are not substan-
tially different between the arms of the study.
All the above mentioned data will be recorded in the Case
Report Form and later stored in computer database. At the
end of the study the final statistical examination will be
carried out.
An interim statistical examination of the data will be done
every 3 months during the period of patients' inclusion in
the study. Then at the end of every completed follow-up
period (1-month, 6-months).
The statistical analysis will be carried out using Epi Info
2000, Version 1.1 software package (Dean AG, Arner TG,
Sangam S, Sunki GG, Friedman R, Lantinga M, Zubieta JC,
Sullivan KM, Smith DC. Epi Info 2000, a database and sta-
tistics program for public health professionals for use on
Windows 95, 98, NT, and 2000 computers; Centers for
Disease Control and Prevention, Atlanta, Georgia, USA,
2000)
No incentives are planned for the patients regarding the
operation or the follow-up.
The study will take approximately 6 months – 1 year for
the inclusion period. According to the number of AC
managed monthly, the duration of the inclusion period
can be approximately of 1 year to reach the number of
about 42 enrolled patients.
An interim report is planned at the end of any completed
follow-up period.
The trial has been registered with the ClinicalTrials.gov
Identifier: NCT00746850 http://clinicaltrials.gov/ct2/
show/NCT00746850?show_desc=Y#desc.
Discussion
AC is a common disease. Any improvement in this field
will benefit many patients reducing morbidity, mortality,
conversion rate, operation time, hospital stay, postopera-
tive pain, return to normal activity and aesthetic result. All
our patients will be informed about the study and an
informed consent will be obtained. There will not be
inconveniences caused to the patients. All the medical
informations obtained from the patients will be kept con-
fidentially among the research scientists conducting the
study. The patients will be free to withdrawn from the
study, whenever they want without any obligation.
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